







































EB = elementary body; IFN = interferon; PCR = polymerase chain reaction; RB = reticulate body.
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Introduction: the Chlamydiae
All Chlamydia species are obligate intracellular bacterial
parasites, and all are pathogenic to their various hosts [1].
Chlamydia trachomatis and  Chlamydia pneumoniae are
human pathogens; the former being the etiologic agent for
trachoma as well as a prevalent sexually transmitted bac-
terium, while C. pneumoniae is a respiratory pathogen
responsible for community-acquired pneumonia. Both
species disseminate from their sites of primary infection,
and when they do so these organisms often take up long-
term residence at distant anatomic locations. At sites of
their dissemination, neither C. trachomatis nor C. pneu-
moniae produces any known toxins. Rather, both species
may elicit a powerful immunopathogenic response that in
turn can engender various diseases, one of which is
inflammatory arthritis [2]. In some individuals with acute
Chlamydia-associated arthritis, the disease can become
chronic. This article focuses on chronic arthritides attribut-
able, or potentially attributable, to disseminated, persistent
infection by the Chlamydiae, and is intended primarily to
stimulate discussion among researchers and clinicians
regarding the unusual biology of these pathogens in rela-
tion to chronic disease. It is also intended to elicit discus-
sion as to how knowledge of the biological attributes of
chlamydial persistence might influence development of
new therapies for treatment of that disease.
The chlamydial developmental cycle
According to classic microbiological description, all
Chlamydiae undergo a biphasic developmental cycle [3].
In the first phase, the infectious extracellular form of the
organism (the elementary body [EB]) locates and binds to
an appropriate eukaryotic host cell. These host cells are
usually epithelial or epithelia-like cells, although several
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studies have indicated that other cell types can be
infected. The host cell receptor to which Chlamydiae bind
has not been firmly established. Following binding, the
organism is brought into a membrane-bound cytoplasmic
inclusion, within which it reorganizes into the metabolically
active form, the reticulate body (RB). During this intracellu-
lar phase, the RBs undergo several rounds of cell division.
At the termination of this active growth process, most divid-
ing RBs reorganize back to the EB form and are released
from the host cell via lysis or exocytosis. Released EBs
then find new host cells to propagate infection. This stan-
dard view of the developmental cycle is derived primarily
from in vitro studies using infected host cells ‘permissive’
for active chlamydial growth. C. trachomatis infecting HeLa
cells requires approximately 50 hours to complete the
developmental cycle. For C. pneumoniae, the standard in
vitro host cell type is Hep-2, and the developmental cycle
requires about 72 hours for completion.
Chlamydial persistence
Recent research results have modified this standard under-
standing of chlamydial growth characteristics in disease
and other contexts. It is now clear that, following dissemi-
nation to distant anatomic sites, both C. trachomatis and
C. pneumoniae can establish long-term infections at those
sites; in this context, details of the organisms’ passage
through the normal developmental cycle and their overall
metabolic characteristics differ from those of actively
growing  Chlamydiae. This modified biological state is
referred to as ‘persistence’, a term intended primarily to
indicate the changed metabolic and other characteristics
that underlie the altered developmental cycle, while at the
same time reflecting the organisms’ tendency to engage in
long-term infection at some sites of their dissemination [4].
Chlamydiae enter the persistent state in vivo in disease
contexts, including chronic Chlamydia-associated arthritis,
and they can be induced to persistence in in vitro model
systems (for example [4–6]). Observations using infected
‘permissive’ host cell types in culture treated with IFNγ
have proved to be important [4]. In these studies, it was
shown that C. trachomatis cells in cytoplasmic inclusions
within IFNγ-treated host cells assume an aberrant morpho-
logic form. Similar aberrantly shaped forms have also been
identified for this organism infecting normal human mono-
cytes in culture in the absence of IFNγ treatment [6]. Per-
sistent organisms show a suite of unusual transcriptional,
and therefore presumably metabolic, characteristics (see
later). Essentially identical attributes have been demon-
strated for C. pneumoniae infecting IFNγ-treated Hep-2
cells, suggesting that these properties are common to all
Chlamydiae in the persistent state (for example [7,8]).
The biology of persistence
As indicated by the earlier discussion, many aspects of
the biology of chlamydial persistence are significantly
different from those of standard, active infection. Persis-
tent C. trachomatis cells reside primarily within monocyte/
macrophages in synovial tissue, and in this state they are
metabolically active but morphologically aberrant [9,10].
Moreover, persistent C. trachomatis cells severely
decrease production of new infectious EBs, reflecting the
fact that the organisms are arrested at a late stage of the
developmental cycle [4–6]. Studies have demonstrated
that transcription of omp1, encoding the immunodominant
major outer membrane protein of this organism, is attenu-
ated in the persistent state, while expression of hsp60,
encoding a highly immunogenic protein, is upregulated
(for example [4,10,11]). Other transcriptional differences
between actively growing and persistent C. trachomatis
cells have been reported. For example, genes whose
products are involved in DNA replication and partition are
expressed during both active growth and persistence, but
genes whose products are required for cytokinesis are
downregulated during the latter state [12]. This attribute is
also found in persistent C. pneumoniae, as are most other
characteristics of persistence already discussed for C. tra-
chomatis [4,8]. Interestingly, expression of genes encod-
ing enzymes of the C. trachomatis glycolytic and pentose
phosphate pathways are downregulated during persis-
tence (Gérard et al., manuscript submitted).
While we have some understanding of the detailed biology
of chlamydial persistence, that understanding is rather
minimal. Moreover, it is almost exclusively descriptive since
we do not understand the molecular mechanisms underlying
most biological characteristics shown by persistent
C. trachomatis and  C. pneumoniae. However, as already
mentioned, those characteristics have been demonstrated
for C. trachomatis both in in vitro models of persistence and
in vivo in joint materials from patients with chronic Chlamy-
dia-associated arthritis (for example [6,9,10]), and they
unquestionably represent meaningful chlamydial adaptations
for maintenance of long-term infection. Available data thus
argue that persistence is a normal, perhaps the normal, state
for  C. trachomatis and  C. pneumoniae during long-term
infection in vivo. The data also suggest that active growth, as
represented by the standard developmental cycle from EBs
to RBs and back to EBs, may be primarily required for con-
tinued high level transmission of the organisms.
Chlamydia-associated arthritis
A relatively small proportion of individuals who acquire a
genital infection with C. trachomatis develop acute inflam-
matory (reactive) arthritis, and only a portion of those
patients proceed to chronic disease [13]. It has never been
clear why some Chlamydia-infected individuals develop
arthritis whereas others do not, and we do not understand
why only a subset of patients who do develop acute
disease proceed to chronicity. Clearly, both aspects are at
least partly a function of host genetic background, but
there may also be as yet unknown genetic or other charac-







































Studies have shown that C. trachomatis reaches the joint
from the urogenital system via circulating monocytes [2],
and that monocytes/macrophages are the common host
cells for persistent organisms during long-term infection of
synovial tissue. It is not known how long a period is
required for transit to the joint, whether C. trachomatis
cells are already persistent on arrival in the joint, or
whether that state develops only after the organisms are
stably in place. We do know from in vitro studies,
however, that C. trachomatis cells enter the persistent
state within about 48 hours post-infection of normal
human peripheral monocytes, that they then alter expres-
sion of several important genes, including increasing tran-
scription of their hsp60 gene [6,12], and that acute
arthritis only develops after 1 week or more of post-genital
infection [13]. These observations suggest that Chlamy-
diae are in fact in the persistent state as they reach the
joint, in turn suggesting that even acute disease is elicited
by persistent, rather than actively growing, organisms. The
observations further suggest that the immunogenic hsp60
protein produced by persistent Chlamydiae is in large part
responsible for eliciting synovial inflammation in both
acute and chronic disease. We therefore argue that
rheumatologists treating patients with chronic Chlamydia-
associated arthritis, and probably also those with acute
disease, must contend with persistent organisms rather
than actively growing ones, and with the altered biology
that characterizes the persistent state. Indeed, in our view,
persistence should be considered the usual state of the
organism in Chlamydia-associated arthritis.
We have no data to indicate how long infected mono-
cyte/macrophages endure in synovial tissue, or how long
the organisms can exist within them in the persistent state.
It would be of interest, and also of clinical importance, to
know the answer to these questions. Importantly, we also
do not know whether C. trachomatis is fully cleared from
the synovium in those patients with acute Chlamydia-
associated arthritis who do not proceed to chronic
disease, or whether organisms can remain at that site in a
persistent but subclinical state. Another important ques-
tion is why many patients with chronic Chlamydia-associ-
ated arthritis cycle between active and quiescent disease.
For both clinical/therapeutic and scientific reasons, all
these are critical issues.
Treatment of persistent synovial Chlamydiae
Antibiotic treatment of active cervical and urethral C.
trachomatis infections is standard, and such regimens are
effective in stopping growth of the organism [14].
However, antibiotic treatment of persistent organisms in
the synovium has proved to be disappointing; while some
groups have reported improvement in patients with
Chlamydia-associated arthritis following antibiotic treat-
ment (for example [15]), other groups have reported little
or none (for example [16,17]). To a limited extent, such
inconsistent outcomes can be traced to the antibiotics
used, since not all such drugs have equal efficacy against
C. trachomatis. Few data exist, however, concerning the
synovial accessibility of any antibiotic following standard
oral or other administration. While joints are well vascular-
ized, suggesting little limitation on such accessibility, it
would still probably be of value to determine effective con-
centrations of anti-chlamydial drugs in the joint for patients
with Chlamydia-associated arthritis.
The efficacy of antibiotic treatment for C. trachomatis is
usually assessed using in vitro systems in which drug and
chlamydial EBs are added simultaneously, or nearly so, to
permissive host cells in culture. Patients presenting with a
urogenital infection by this bacterium, however, already
have organisms well progressed into the developmental
cycle, and those with chronic reactive arthritis have persis-
tent organisms. This and other groups have suggested
that drug determinations be carried out by addition to
already-infected host cells in culture after inclusions have
been formed [2,18]. Moreover, we have provided evi-
dence that when such a system is employed, the effect of
some antibiotics (ciprofloxacin and orofloxacin) on C. tra-
chomatis growth is unexpected [19]. Specifically, in our
study, treatment of already-infected permissive host cells
with standard concentrations of either drug induced the
persistent state, rather than clearing the organism. This
result would not have been observed had the determina-
tion been carried out in the standard manner. In vitro defi-
nition of the minimal inhibitory concentration of any
antibiotic for C. trachomatis or  C. pneumoniae by the
standard method thus appears inappropriate for patients
with either acute or chronic Chlamydia-associated arthri-
tis, and it may not even be optimal for individuals with
active urogenital infection.
The question remains whether eradication of persistent
Chlamydiae in the synovium can be achieved via antibiotic
treatment alone. Even if such drugs function reasonably
effectively for active infection of the urogenital or other
systems, it does not necessarily follow that they can and
will do so in the case of persistent organisms. We suggest
that a useful approach to treatment of patients with
Chlamydia-associated arthritis would be to define some
means by which persistent organisms can be induced to
return to the active developmental cycle, thereby making
them more accessible to antibiotic activity.
C. pneumoniae and arthritis
Several laboratories have demonstrated the synovial pres-
ence of bacterial DNA and/or antigens from organisms not
traditionally associated with joint disease (for example
[20–22]). It is not clear whether joint pathogenesis is initi-
ated or maintained by these organisms, but it is of interest
that DNA from C. pneumoniae has been found in synovial
tissues of a small but still significant number of patients
Available online http://arthritis-research.com/content/4/1/005with various arthritides [23–25]. Our own analysis showed
that when synovial tissue samples from individuals with
various arthritides were screened, about 13% of patients
were PCR-positive for the organism [24]; the organism is
viable and metabolically active in joint tissue [26]. While it
is well documented that this organism can induce a pow-
erful inflammatory response at sites of its residence [27],
no evidence available to date directly links synovial inflam-
mation with the presence of C. pneumoniae, either in the
actively growing or the persistent state. Interestingly, no
clearly defined pattern of extra-articular clinical features
similar to those known for C. trachomatis-associated
arthritis has been identified in patients PCR-positive for
C. pneumoniae in synovial tissue [24]. The question of
whether this respiratory pathogen is responsible for initia-
tion and/or exacerbation of joint disease thus remains
open. In our opinion, however, it is difficult to argue that
the organism is not involved in joint disease in at least
some patients, given our understanding of the pathobiol-
ogy of C. pneumoniae in other contexts. In any event, the
relationship between C. pneumoniae and inflammatory or
other arthritides is an issue that invites detailed investiga-
tion since, if an etiologic relationship can be demonstrated
between synovial presence of the bacterium and inflam-
matory arthritis, the American College of Rheumatology
criteria for reactive arthritis will have to be altered.
Chlamydial infection and other chronic
arthritides
Beginning with the demonstration of Helicobacter pylori as
an etiologic agent for ulcers, the notion that bacterial, viral,
and probably fungal pathogens can play either an initiating
or exacerbatory role in chronic disease has gained increas-
ing credence. In the case of C. trachomatis, the sequelae of
primary genital infection can be both chronic and severe;
these include not only arthritis, but also fertility deficit in
women and possibly cervical cancer [28,29]. Disseminated
infection by C. pneumoniae has been linked to asthma,
chronic obstructive pulmonary disease [27], atherosclerosis
[30], multiple sclerosis [31,32], Alzheimer’s disease [33],
and other clinical entities including inflammatory arthritis, as
already mentioned. Many of these associations are highly
controversial, but they remain under active investigation.
Rheumatoid arthritis is a relatively common and often
severe degenerative disease characterized by, among
other things, chronic inflammation of the synovium and
altered performance of the immune system. Several inves-
tigators have suggested that the inflammation, the break in
immune self-tolerance, and other characteristics whose
combined consequences include synovial degradation
may be the common end point for a number of diverse
starting points. As reviewed recently, several explanations
have been advanced to account for the initiation of patho-
genesis in rheumatoid arthritis [34]. One long-standing
idea postulates an infectious etiology, perhaps operating
in part through molecular mimicry, to elicit a host auto-
immune response.
The idea that rheumatoid arthritis may have an infectious eti-
ology is not new. Indeed, the disease was referred to as
‘infectious arthritis’ in the mid-20th century, and one recent
editorial has suggested that this disease may be a form of
reactive arthritis [35]. However, despite continuing interest
in this idea, no viral or bacterial pathogen has been unequiv-
ocally shown to be responsible for initiation or maintenance
of pathogenesis in any patient with rheumatoid arthritis.
Interestingly, some recent studies have demonstrated thera-
peutic efficacy for antibiotics in patients with rheumatoid
arthritis [36]; it is not clear from these studies, however,
whether clinical improvement resulted from antimicrobial,
anti-inflammatory, or other activity of the drugs used.
Earlier reports suggested a link between Chlamydia and
rheumatoid arthritis (for example [37]), but to our knowl-
edge this particular study has not been developed further.
An important recent review did specify characteristics
required of candidate pathogens for them to have a role in
this disease [34]. These include persistence or dormancy,
relatively low virulence, and ubiquitous distribution. All
these characteristics are met in relation to the
Chlamydiae. Moreover, it seems probable that the inciting
organism should be present in the synovial fluid or tissue
of patients with rheumatoid arthritis, at least in early
disease, and this has been shown [38]. C. trachomatis,
and possibly C. pneumoniae, may thus prove to be inter-
esting candidates for the initiating agents in rheumatoid
arthritis, at least in a subset of patients.
Conclusions
In this article, we have suggested some reasons for a
realignment of thinking concerning Chlamydia-associated
arthritis, based on research results regarding the basic
biology of C. trachomatis, and to some extent that of
C. pneumoniae. Our purpose has been to elicit discussion
among rheumatologists and researchers as to how infor-
mation regarding chlamydial persistence might refocus
studies of mechanisms of synovial pathogenesis induced
by these organisms in inflammatory arthritis, and perhaps
other chronic arthritides. To a lesser extent, we have also
tried to initiate discussion as to how these new insights
might inform ideas for improvement of treatment of such
joint diseases. In this brief article, it has not been possible
to develop in detail all the bases supporting such realign-
ments, of course, but if meaningful discussion results from
this text then its purpose will have been served.
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